Cannabinoid use in Uveitis; A survey of Vogt-Koyanagi-Harada patients

Track:
Uveitis
What:
Paper Presentation | Présentation d'article
When:
4:05 PM, Friday 25 Jun 2021 (10 minutes)

David J. A. Plemel, Mark D. J. Greve.

Disclosure Block: D.J.A. Plemel: None. M.D.J. Greve: Membership on advisory boards or speakers’ bureaus; Name of for-profit or not-for-profit organization(s); Secure Diagnostic Imaging. Membership on advisory boards or speakers’ bureaus; Description of relationship(s); Director. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Rocky Mountain Collective. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Equity Investment.

Abstract Title:

Cannabinoid use in Uveitis; A survey of Vogt-Koyanagi-Harada patients

Abstract Body:

Purpose: Patients in our clinic have been asking about the evidence for treating chronic uveitis with cannabis products. To the best of our knowledge, there is no evidence to guide such a discussion. This study aims to understand the use of cannabis products as complementary and alternative medicine (CAM) amongst Vogt-Koyanagi-Harada (VKH) patients, as a model of chronic inflammatory eye disease.

Study Design: Survey study. Ethics approval was obtained from the University of Alberta Human Research and Ethics Committee (Pro00098473).

Methods: Patients with VKH were identified from a community retina practice. Patients were called by telephone. Eligible patients who agreed to participate were sent an anonymous online survey regarding their VKH and cannabis use.

Results: Twelve of sixteen (75%) of included patients responded to the survey. Of these, five (5/12; 42%) indicated prior use of cannabis products with the aim of treating their VKH. Three (25%) respondents continue to use cannabis products at least twice weekly for a perceived benefit in VKH management. There are numerous co-morbidities that respondents feel also benefit from the use of cannabis, the most common of which are anxiety and post traumatic stress disorder. Four of five report a preference for high THC products, while smoking is the most preferred method of consumption by three of five.

Conclusions: One quarter of respondents use cannabis products as self-prescribed CAM for VKH. As clinicians, it is important to understand our patients’ prescribed and non-prescription treatments. Basic science and clinical studies will be needed to assess the impact of cannabis products on intraocular inflammation.

Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages